GeneDx and Prognos Health have announced a strategic partnership with the aim of shortening the treatment journey for rare disease patients using real-world data. The partnership provides life science companies access to a comprehensive de-identified dataset specific to rare diseases, which can accelerate the availability of life-saving therapies.
Through this collaboration, GeneDx's de-identified rare disease data, including regularly updated information from its whole genome and whole exome sequencing tests, will be integrated into the Prognos Marketplace. Biopharma companies working with Prognos will receive automatic alerts about clinicians who have newly diagnosed rare disease patients and may benefit from FDA-approved therapies.
The partnership addresses the lengthy diagnostic process for rare diseases, which often takes around eight years, resulting in wasted time without an accurate diagnosis and access to suitable treatments. GeneDx is committed to ending this diagnostic odyssey for patients and their families, and the partnership with Prognos allows them to connect clinicians and patients with appropriate treatment options, ultimately improving health and economic outcomes.
GeneDx has a vast genetic database enriched with rare disease samples from over 1.3 million patients, including more than 450,000 exomes and genomes. Prognos' Marketplace includes de-identified lab and health records for over 325 million patients, along with claims and prescription data, among other data types.
Click here to read the original news story.